The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Treatment of uveal melanoma: where are we now?
Open accessAbstract
Uveal melanoma, a rare subset of melanoma, is the most common primary intraocular malignancy in adults. Despite effective primary therapy, nearly 50% of patients will develop metastatic disease. Outcomes for those with metastatic disease remain dismal due to a lack of effective therapies. The unique biology and immunology of uveal melanoma necessitates the development of dedicated management and treatment approaches. Ongoing efforts seek to optimize the efficacy of targeted therapy and immunotherapy in both the adjuvant and metastatic setting. This review provides a comprehensive, updated overview of disease biology and risk stratification, the management of primary disease, options for adjuvant therapy, and the current status of treatment strategies for metastatic disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.036 · Cited by 2,961
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Delmore, J. E., Issa, G. C., Lemieux, M. E., Rahl, P. B., Shi, J., Jacobs, H. M., Kastritis, E., Gilpatrick, T., Paranal, R. M., Qi, J., et al. (2011) · Cell · doi:10.1016/j.cell.2011.08.017 · Cited by 2,813
Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi
Van Raamsdonk, C. D., Bezrookove, V., Green, G., Bauer, J., Gaugler, L., O’Brien, J. M., Simpson, E. M., Barsh, G. S., & Bastian, B. C. (2009) · Nature · doi:10.1038/nature07586 · Cited by 1,623
Mutations in GNA11 in Uveal Melanoma
Van Raamsdonk, C. D., Griewank, K. G., Crosby, M. B., Garrido, M. C., Vemula, S., Wiesner, T., Obenauf, A. C., Wackernagel, W., Green, G., Bouvier, N., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000584 · Cited by 1,476
Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas
Harbour, J. W., Onken, M. D., Roberson, E. D. O., Duan, S., Cao, L., Worley, L. A., Council, M. L., Matatall, K. A., Helms, C., & Bowcock, A. M. (2010) · Science · doi:10.1126/science.1194472 · Cited by 1,462
Uveal Melanoma: Trends in Incidence, Treatment, and Survival
Singh, A. D., Turell, M. E., & Topham, A. K. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2011.01.040 · Cited by 1,267
Very Long-Term Prognosis of Patients with Malignant Uveal Melanoma
Kujala, E., Ma¨kitie, T., & Kivela¨, T. (2003) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.03-0538 · Cited by 1,045
Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma
Robertson, A. G., Shih, J., Yau, C., Gibb, E. A., Oba, J., Mungall, K. L., Hess, J. M., Uzunangelov, V., Walter, V., Danilova, L., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.003 · Cited by 887
Incidence of noncutaneous melanomas in the U.S.
McLaughlin, C. C., Wu, X., Jemal, A., Martin, H. J., Roche, L. M., & Chen, V. W. (2005) · Cancer · doi:10.1002/cncr.20866 · Cited by 739
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
Das Thakur, M., Salangsang, F., Landman, A. S., Sellers, W. R., Pryer, N. K., Levesque, M. P., Dummer, R., McMahon, M., & Stuart, D. D. (2013) · Nature · doi:10.1038/nature11814 · Cited by 730
(2005) · Archives of Ophthalmology · doi:10.1001/archopht.123.12.1639 · Cited by 621
Feng, X., Degese, M. S., Iglesias-Bartolome, R., Vaque, J. P., Molinolo, A. A., Rodrigues, M., Zaidi, M. R., Ksander, B. R., Merlino, G., Sodhi, A., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.016 · Cited by 563
Falchook, G. S., Lewis, K. D., Infante, J. R., Gordon, M. S., Vogelzang, N. J., DeMarini, D. J., Sun, P., Moy, C., Szabo, S. A., Roadcap, L. T., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70269-3 · Cited by 546
Martin, M., Maßhöfer, L., Temming, P., Rahmann, S., Metz, C., Bornfeld, N., van de Nes, J., Klein-Hitpass, L., Hinnebusch, A. G., Horsthemke, B., et al. (2013) · Nature Genetics · doi:10.1038/ng.2674 · Cited by 542
Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma
Harbour, J. W., Roberson, E. D. O., Anbunathan, H., Onken, M. D., Worley, L. A., & Bowcock, A. M. (2013) · Nature Genetics · doi:10.1038/ng.2523 · Cited by 516
Onken, M. D., Worley, L. A., Char, D. H., Augsburger, J. J., Correa, Z. M., Nudleman, E., Aaberg, T. M., Altaweel, M. M., Bardenstein, D. S., Finger, P. T., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.02.017 · Cited by 506
Metastatic disease from uveal melanoma: treatment options and future prospects
Carvajal, R. D., Schwartz, G. K., Tezel, T., Marr, B., Francis, J. H., & Nathan, P. D. (2017) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2016-309034 · Cited by 438
Self-citationCarvajal, R. D., Sosman, J. A., Quevedo, J. F., Milhem, M. M., Joshua, A. M., Kudchadkar, R. R., Linette, G. P., Gajewski, T. F., Lutzky, J., Lawson, D. H., et al. (2014) · JAMA · doi:10.1001/jama.2014.6096 · Cited by 433
Self-citationClinical outcomes in metastatic uveal melanoma treated with PD‐1 and PD‐L1 antibodies
Algazi, A. P., Tsai, K. K., Shoushtari, A. N., Munhoz, R. R., Eroglu, Z., Piulats, J. M., Ott, P. A., Johnson, D. B., Hwang, J., Daud, A. I., et al. (2016) · Cancer · doi:10.1002/cncr.30258 · Cited by 393
Self-citationThe Role of Tissue Factor and Factor VIIa in Hemostasis
Mackman, N. (2009) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e31819bceb1 · Cited by 335
Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma
Moore, A. R., Ceraudo, E., Sher, J. J., Guan, Y., Shoushtari, A. N., Chang, M. T., Zhang, J. Q., Walczak, E. G., Kazmi, M. A., Taylor, B. S., et al. (2016) · Nature Genetics · doi:10.1038/ng.3549 · Cited by 314
Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4
Johansson, P., Aoude, L. G., Wadt, K., Glasson, W. J., Warrier, S. K., Hewitt, A. W., Kiilgaard, J. F., Heegaard, S., Isaacs, T., Franchina, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.6614 · Cited by 303
PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma
Field, M. G., Decatur, C. L., Kurtenbach, S., Gezgin, G., van der Velden, P. A., Jager, M. J., Kozak, K. N., & Harbour, J. W. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2071 · Cited by 293
Chandran, S. S., Somerville, R. P. T., Yang, J. C., Sherry, R. M., Klebanoff, C. A., Goff, S. L., Wunderlich, J. R., Danforth, D. N., Zlott, D., Paria, B. C., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30251-6 · Cited by 292
Self-citationHistone Deacetylase Inhibitors Induce Growth Arrest and Differentiation in Uveal Melanoma
Landreville, S., Agapova, O. A., Matatall, K. A., Kneass, Z. T., Onken, M. D., Lee, R. S., Bowcock, A. M., & Harbour, J. W. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0946 · Cited by 289
Effectiveness of Treatments for Metastatic Uveal Melanoma
Augsburger, J. J., Corrêa, Z. M., & Shaikh, A. H. (2009) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2009.01.023 · Cited by 288
Zimmer, L., Vaubel, J., Mohr, P., Hauschild, A., Utikal, J., Simon, J., Garbe, C., Herbst, R., Enk, A., Kämpgen, E., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0118564 · Cited by 269
Uveal Melanomas with SF3B1 Mutations
Yavuzyigitoglu, S., Koopmans, A. E., Verdijk, R. M., Vaarwater, J., Eussen, B., van Bodegom, A., Paridaens, D., Kiliç, E., & de Klein, A. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.01.023 · Cited by 267
The Association Between Host Susceptibility Factors and Uveal Melanoma: A Meta-analysis
Weis, E. (2006) · Archives of Ophthalmology · doi:10.1001/archopht.124.1.54 · Cited by 236
Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery
Fu, L.-L., Tian, M., Li, X., Li, J.-J., Huang, J., Ouyang, L., Zhang, Y., & Liu, B. (2015) · Oncotarget · doi:10.18632/oncotarget.3551 · Cited by 221
Kuk, D., Shoushtari, A. N., Barker, C. A., Panageas, K. S., Munhoz, R. R., Momtaz, P., Ariyan, C. E., Brady, M. S., Coit, D. G., Bogatch, K., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0522 · Cited by 201
Self-citationEvidence-Based Estimates of Outcome in Patients Irradiated for Intraocular Melanoma
Gragoudas, E. (2002) · Archives of Ophthalmology · doi:10.1001/archopht.120.12.1665 · Cited by 192
Intermittent and Chronic Ultraviolet Light Exposure and Uveal Melanoma
Shah, C. P., Weis, E., Lajous, M., Shields, J. A., & Shields, C. L. (2005) · Ophthalmology · doi:10.1016/j.ophtha.2005.04.020 · Cited by 190
Recent developments in prognostic and predictive testing in uveal melanoma
Field, M. G., & Harbour, J. W. (2014) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000051 · Cited by 167
Spagnolo, F., Caltabiano, G., & Queirolo, P. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.01.002 · Cited by 165
Quality of Life After Iodine 125 Brachytherapy vs Enucleation for Choroidal Melanoma
Collaborative Ocular Melanoma Study–Quality of Life Study Group (2006) · Archives of Ophthalmology · doi:10.1001/archopht.124.2.226 · Cited by 150
Field, M. G., Durante, M. A., Decatur, C. L., Tarlan, B., Oelschlager, K. M., Stone, J. F., Kuznetsoff, J. N., Bowcock, A. M., Kurtenbach, S., & Harbour, J. W. (2016) · Oncotarget · doi:10.18632/oncotarget.10962 · Cited by 134
Xu, H., Stabile, L. P., Gubish, C. T., Gooding, W. E., Grandis, J. R., & Siegfried, J. M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3339 · Cited by 131
Crizotinib, a c-Met Inhibitor, Prevents Metastasis in a Metastatic Uveal Melanoma Model
Surriga, O., Rajasekhar, V. K., Ambrosini, G., Dogan, Y., Huang, R., & Schwartz, G. K. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0499 · Cited by 118
PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma
Gezgin, G., Luk, S. J., Cao, J., Doğrusöz, M., van der Steen, D. M., Hagedoorn, R. S., Krijgsman, D., van der Velden, P. A., Field, M. G., Luyten, G. P. M., et al. (2017) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2017.0729 · Cited by 118
Agarwala, S. S., Eggermont, A. M. M., O'Day, S. J., & Zager, J. S. (2013) · Cancer · doi:10.1002/cncr.28480 · Cited by 112
Digital PCR Validates 8q Dosage as Prognostic Tool in Uveal Melanoma
Versluis, M., de Lange, M. J., van Pelt, S. I., Ruivenkamp, C. A. L., Kroes, W. G. M., Cao, J., Jager, M. J., Luyten, G. P. M., & van der Velden, P. A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0116371 · Cited by 108
A phase 2 study of tremelimumab in patients with advanced uveal melanoma
Joshua, A. M., Monzon, J. G., Mihalcioiu, C. L. D., Hogg, D., Smylie, M., & Cheng, T. (2015) · Melanoma Research · doi:10.1097/cmr.0000000000000175 · Cited by 105
Biology of advanced uveal melanoma and next steps for clinical therapeutics
Luke, J. J., Triozzi, P. L., McKenna, K. C., Meir, E. G. V., Gershenwald, J. E., Bastian, B. C., Gutkind, J. S., Bowcock, A. M., STREICHER, H. Z., Patel, P. M., et al. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12304 · Cited by 104
Self-citationInhibition of Mutant GNAQ Signaling in Uveal Melanoma Induces AMPK-Dependent Autophagic Cell Death
Ambrosini, G., Musi, E., Ho, A. L., de Stanchina, E., & Schwartz, G. K. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1020 · Cited by 104
Identification of an Immunogenic Subset of Metastatic Uveal Melanoma
Rothermel, L. D., Sabesan, A. C., Stephens, D. J., Chandran, S. S., Paria, B. C., Srivastava, A. K., Somerville, R. P. T., Wunderlich, J. R., Lee, C. R., Xi, L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2294 · Cited by 102
Genomic Profile of 320 Uveal Melanoma Cases: Chromosome 8p-Loss and Metastatic Outcome
Ewens, K. G., Kanetsky, P. A., Richards‐Yutz, J., Al-Dahmash, S. A., Luca, M. C. D., Bianciotto, C. G., Shields, C. L., & Ganguly, A. A. (2013) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.13-12195 · Cited by 101
Valsecchi, M. E., Terai, M., Eschelman, D. J., Gonsalves, C. F., Chervoneva, I., Shields, J. A., Shields, C. L., Yamamoto, A., Sullivan, K. L., Laudadio, M., et al. (2015) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2014.11.037 · Cited by 98
Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies
Komatsubara, K. M., & Carvajal, R. D. (2017) · Current Oncology Reports · doi:10.1007/s11912-017-0606-5 · Cited by 94
Self-citationSchmittel, A. H., Schmidt‐Hieber, M., Martus, P., Bechrakis, N., Schuster, R., Siehl, J., Foerster, M. H., Thiel, E., & Keilholz, U. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl309 · Cited by 93
Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma
Karydis, I., Chan, P. Y., Wheater, M. J., Arriola, E., Szlosarek, P. W., & Ottensmeier, C. H. H. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1143997 · Cited by 91
Bhatia, S., Moon, J., Margolin, K. A., Weber, J. S., Lao, C. D., Othus, M. K. D., Aparicio, A. M., Ribas, A., & Sondak, V. K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048787 · Cited by 89
Clinical Management of Uveal and Conjunctival Melanoma.
Blum, E. S., Yang, J., Komatsubara, K. M., & Carvajal, R. D. (2016) · PubMed · Cited by 75
Self-citationDAUD, A. I., Kluger, H. M., Kurzrock, R., Schimmöller, F., Weitzman, A., Samuel, T. A., Moussa, A. H., Gordon, M. S., & Shapiro, G. I. (2017) · British Journal of Cancer · doi:10.1038/bjc.2016.419 · Cited by 73
Musi, E., Ambrosini, G., de Stanchina, E., & Schwartz, G. K. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0550 · Cited by 65
Kivelä, T., Puusaari, I., & Damato, B. E. (2003) · Ophthalmology · doi:10.1016/j.ophtha.2003.02.001 · Cited by 63
BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cells
Ambrosini, G., Sawle, A., Musi, E., & Schwartz, G. K. (2015) · Oncotarget · doi:10.18632/oncotarget.5179 · Cited by 63
Shoushtari, A. N., Kudchadkar, R. R., Panageas, K. S., Murthy, R. K., Jung, M., Shah, R., O'Donnell, B., Khawaja, T. T., Shames, Y., Prempeh-Keteku, N. A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.9511 · Cited by 58
Self-citationPuusaari, I., Damato, B. E., & Kivelä, T. (2006) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-006-0461-9 · Cited by 47
Wu, X., Zhou, J. M., Rogers, A. M., Janne, P. A., Benedettini, E., Loda, M. F., & Hodi, F. S. (2012) · Melanoma Research · doi:10.1097/cmr.0b013e3283507ffd · Cited by 46
Primary photodynamic therapy with verteporfin for small pigmented posterior pole choroidal melanoma
Fabian, I. D., Stacey, A. W., Papastefanou, V. P., et al. (2017) · Eye · doi:10.1038/eye.2017.22 · Cited by 45
Expression of Angiogenic Factors Cyr61 and Tissue Factor in Uveal Melanoma
Walker, T. M., van Ginkel, P. R., Gee, R. L., Ahmadi, H., Subramanian, L., Ksander, B. R., Meisner, L. F., Albert, D. M., & Polans, A. S. (2002) · Archives of Ophthalmology · doi:10.1001/archopht.120.12.1719 · Cited by 44
Skewed Expression of the Genes Encoding Epigenetic Modifiers in High-Risk Uveal Melanoma
Herlihy, N. S., Doğrusöz, M., van Essen, T. H., Harbour, J. W., van der Velden, P. A., van Eggermond, M. C. J. A., Haasnoot, G. W., van den Elsen, P. J., & Jager, M. J. (2015) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.14-15250 · Cited by 42
Cited by
Saginala, K., Barsouk, A., Aluru, J. S., Rawla, P., & Barsouk, A. (2021) · Medical Sciences · doi:10.3390/medsci9040063 · Cited by 514
Metadata
- Authors
- Yang, J., Manson, D. K., Marr, B. P., & Carvajal, R. D.
- Venue
- Therapeutic Advances in Medical Oncology
- Publisher
- SAGE Publications
- Published
- 2018-01-01
- Volume
- 10
- Pages
- 1758834018757175-1758834018757175
- ISSN
- 1758-8340 (ISSN-L)
- 1758-8359
- OpenAlex
- W2793234561
- Cited by
- 300
- References
- 65
- FWCI
- 32.48
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.